Cargando…

A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention

BACKGROUND: Identifying female carriers of BRCA1 and BRCA2 mutations is imperative for prevention of ovarian cancer and breast cancer. There are five major histologic subtypes of ovarian cancer and high grade serous cancer (the most common) is reported in 75–100% of BRCA1 and BRCA2 mutation carriers...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanley, Gillian E., McAlpine, Jessica N., Miller, Dianne, Huntsman, David, Schrader, Kasmintan A., Blake Gilks, C., Mitchell, Gillian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838948/ https://www.ncbi.nlm.nih.gov/pubmed/29506471 http://dx.doi.org/10.1186/s12885-018-4153-8

Ejemplares similares

Absence of BRCA/FMR1 Correlations in Women with Ovarian Cancers
por: Gleicher, Norbert, et al.
Publicado: (2014)

Opportunistic salpingectomy for ovarian cancer prevention
por: Hanley, Gillian E., et al.
Publicado: (2015)

Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention
por: Hanley, Gillian E., et al.
Publicado: (2022)

Ovarian carcinoma histotype in Lynch syndrome
por: Gilks, C. Blake, et al.
Publicado: (2017)

Germline Testing and Somatic Tumor Testing for BRCA1/2 Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?
por: Kwon, Janice S., et al.
Publicado: (2022)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
por: Maistro, Simone, et al.
Publicado: (2016)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
por: Ferreyra, Yomali, et al.
Publicado: (2023)

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
por: Ligtenberg, M J L, et al.
Publicado: (1999)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

BRCA1 and BRCA2 Germline Mutations Screening in Algerian Breast/Ovarian Cancer Families
por: Cherbal, Farid, et al.
Publicado: (2010)

BRCA germline mutation test for all woman with ovarian cancer?
por: Paradiso, A. V., et al.
Publicado: (2019)

BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families
por: Claes, K, et al.
Publicado: (2004)

Screening for germline rearrangements in BRCA1 and BRCA2 in Norwegian families with breast or breast/ovarian cancer
por: Van Ghelue, M, et al.
Publicado: (2005)

Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome
por: Ashour, Mohamed, et al.
Publicado: (2019)

An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers
por: Przybytkowski, Ewa, et al.
Publicado: (2020)

Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients
por: Zhang, Yunuo, et al.
Publicado: (2022)

BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors
por: Cremona, Mattia, et al.
Publicado: (2022)

Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance
por: Cham, Stephanie, et al.
Publicado: (2022)

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer
por: Eccleston, Anthony, et al.
Publicado: (2017)

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
por: Press, Joshua Z, et al.
Publicado: (2008)

Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational Status
por: Logue, Chloe A., et al.
Publicado: (2021)

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer
por: Lee, Yong Jae, et al.
Publicado: (2020)

A multi-center study to evaluate the impact of germline BRCA1 and BRCA2 mutations on ovarian cancer survival
por: Bolton, KL, et al.
Publicado: (2012)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada
por: Arora, Nimisha, et al.
Publicado: (2018)

Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer
por: Cao, Wen-Ming, et al.
Publicado: (2016)

Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer
por: Nicolussi, Arianna, et al.
Publicado: (2019)

Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects
por: Peixoto, Ana, et al.
Publicado: (2020)

Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer
por: Bekos, Christine, et al.
Publicado: (2021)

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
por: Manchana, Tarinee, et al.
Publicado: (2020)

The BRCA Gene in Epithelial Ovarian Cancer
por: Sánchez-Lorenzo, Luisa, et al.
Publicado: (2022)

Characterization of BRCA Deficiency in Ovarian Cancer
por: Barbero, Giovanna, et al.
Publicado: (2023)

Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations
por: Jorge, Soledad, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Germline and Somatic BRCA Testing in Patients With Advanced Ovarian Cancer
por: Jang, Jaehyeok, et al.
Publicado: (2023)

Nipple aspiration and ductal lavage in women with a germline BRCA1 or BRCA2 mutation
por: Mitchell, Gillian, et al.
Publicado: (2005)

Biallelic BRCA Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline BRCA1/2 Carriers
por: Wineland, Dylane, et al.
Publicado: (2023)

The Features of BRCA1 and BRCA2 Germline Mutations in Hakka Ovarian Cancer Patients: BRCA1 C.536 A>T Maybe a Founder Mutation in This Population
por: Luo, Yu, et al.
Publicado: (2022)

Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations
por: Wang-Gohrke, S, et al.
Publicado: (1999)

Genetic testing in Poland and Ukraine: should comprehensive germline testing of BRCA1 and BRCA2 be recommended for women with breast and ovarian cancer?
por: Nguyen-Dumont, Tu, et al.
Publicado: (2020)

Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia
por: Ben Ayed-Guerfali, Dorra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b16ttq6shlug6tkloqe2qcc1tr